Jonathan Roy Honey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan Roy Honey has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Carnicer-Lombarte
Department of Biomedical Engineering, City University of Hong Kong
1 shared publication Andy Langford
Cruse Bereavement Care, Richmond, UK
1 shared publication- Caroline Pearce
Advanced Care Research Centre, University of Edinburgh, Usher Building, Little France Road, EH16 4UX, United Kingdom; OPENSpace Research Centre, Edinburgh College of Art, University of Edinburgh, Lauriston Place, Edinburgh, EH3 9DF, United Kingdom
1 shared publication - Claire Burton
Arthritis UK Primary Care Centre, School of Medicine, Keele University, ST5 5BG, UK
1 shared publication Claire Henry
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
1 shared publication- Damiano Giuseppe Barone
Electrical Engineering Division, Department of Engineering, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 23 November 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (1) , 40-48
Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review
Objective: Musculoskeletal symptoms are commonly reported following acute COVID‐19. It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seeks to identify evidence for an association between acute COVID‐19 and subsequent iRMD diagnosis.Methods: A rapid review of the literature using a systematic search of Medline, EMBASE and two COVID‐19 databases was undertaken until August 2022. Case studies, case series, cross‐sectional, case‐control, and cohort studies reporting patients with an incident iRMD following COVID‐19 were included. Title and abstract screening were conducted by one reviewer and full text screening by two reviewers. Data extraction and quality appraisal were by one reviewer, with a second verifying. Study‐type specific critical appraisal tools were used.Results: Results were narratively synthesized. A total of 80 studies were included (69 case reports, 10 case series and 1 cross‐sectional study). Commonly reported iRMDs were “reactive arthropathies” (n = 47), “inflammatory arthropathies unspecified” (n = 18), rheumatoid arthritis (n = 12) and systemic lupus erythematosus (n = 11). The cross‐sectional study reported 37% of those with COVID‐19 developed “post COVID arthritis.” Time from diagnosis of COVID‐19 to iRMD presentation ranged from 0 to 120 days. Several mechanisms were proposed to explain the association between COVID‐19 and iRMD development: autoimmune processes, aberrant inflammatory responses, colonization of joint spaces, direct damage from the severe acute respiratory syndrome coronavirus 2 virus and genetic predisposition.Conclusion: The level of evidence of the studies included in this review was low and the quality generally poor. Prospective observational studies are required to confirm associations and likely impact of post COVID‐19 iRMDs at a population level.
- 23 November 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (1) , 40-48
Open AccessSummarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review
Objective: Musculoskeletal symptoms are commonly reported following acute COVID‐19. It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seeks to identify evidence for an association between acute COVID‐19 and subsequent iRMD diagnosis.Methods: A rapid review of the literature using a systematic search of Medline, EMBASE and two COVID‐19 databases was undertaken until August 2022. Case studies, case series, cross‐sectional, case‐control, and cohort studies reporting patients with an incident iRMD following COVID‐19 were included. Title and abstract screening were conducted by one reviewer and full text screening by two reviewers. Data extraction and quality appraisal were by one reviewer, with a second verifying. Study‐type specific critical appraisal tools were used.Results: Results were narratively synthesized. A total of 80 studies were included (69 case reports, 10 case series and 1 cross‐sectional study). Commonly reported iRMDs were “reactive arthropathies” (n = 47), “inflammatory arthropathies unspecified” (n = 18), rheumatoid arthritis (n = 12) and systemic lupus erythematosus (n = 11). The cross‐sectional study reported 37% of those with COVID‐19 developed “post COVID arthritis.” Time from diagnosis of COVID‐19 to iRMD presentation ranged from 0 to 120 days. Several mechanisms were proposed to explain the association between COVID‐19 and iRMD development: autoimmune processes, aberrant inflammatory responses, colonization of joint spaces, direct damage from the severe acute respiratory syndrome coronavirus 2 virus and genetic predisposition.Conclusion: The level of evidence of the studies included in this review was low and the quality generally poor. Prospective observational studies are required to confirm associations and likely impact of post COVID‐19 iRMDs at a population level.
- Open Access
- 30 May 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 79, 103900
“Lessons from the pandemic: How can we enhance surgical training in undergraduate education?"
- 30 May 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 79, 103900
Open Access“Lessons from the pandemic: How can we enhance surgical training in undergraduate education?"
- Open Access
- 16 August 2021
- Published by MDPI AG in Biosensors
- Vol. 11 (8) , 275
Large Animal Studies to Reduce the Foreign Body Reaction in Brain–Computer Interfaces: A Systematic Review
Brain–computer interfaces (BCI) are reliant on the interface between electrodes and neurons to function. The foreign body reaction (FBR) that occurs in response to electrodes in the brain alters this interface and may pollute detected signals, ultimately impeding BCI function. The size of the FBR is influenced by several key factors explored in this review; namely, (a) the size of the animal tested, (b) anatomical location of the BCI, (c) the electrode morphology and coating, (d) the mechanics of electrode insertion, and (e) pharmacological modification (e.g., drug eluting electrodes). Trialing methods to reduce FBR in vivo, particularly in large models, is important to enable further translation in humans, and we systematically reviewed the literature to this effect. The OVID, MEDLINE, EMBASE, SCOPUS and Scholar databases were searched. Compiled results were analysed qualitatively. Out of 8388 yielded articles, 13 were included for analysis, with most excluded studies experimenting on murine models. Cats, rabbits, and a variety of breeds of minipig/marmoset were trialed. On average, over 30% reduction in inflammatory cells of FBR on post mortem histology was noted across intervention groups. Similar strategies to those used in rodent models, including tip modification and flexible and sinusoidal electrode configurations, all produced good effects in histology; however, a notable absence of trials examining the effect on BCI end-function was noted. Future studies should assess whether the reduction in FBR correlates to an improvement in the functional effect of the intended BCI.
- 16 August 2021
- Published by MDPI AG in Biosensors
- Vol. 11 (8) , 275
Open AccessLarge Animal Studies to Reduce the Foreign Body Reaction in Brain–Computer Interfaces: A Systematic Review
Brain–computer interfaces (BCI) are reliant on the interface between electrodes and neurons to function. The foreign body reaction (FBR) that occurs in response to electrodes in the brain alters this interface and may pollute detected signals, ultimately impeding BCI function. The size of the FBR is influenced by several key factors explored in this review; namely, (a) the size of the animal tested, (b) anatomical location of the BCI, (c) the electrode morphology and coating, (d) the mechanics of electrode insertion, and (e) pharmacological modification (e.g., drug eluting electrodes). Trialing methods to reduce FBR in vivo, particularly in large models, is important to enable further translation in humans, and we systematically reviewed the literature to this effect. The OVID, MEDLINE, EMBASE, SCOPUS and Scholar databases were searched. Compiled results were analysed qualitatively. Out of 8388 yielded articles, 13 were included for analysis, with most excluded studies experimenting on murine models. Cats, rabbits, and a variety of breeds of minipig/marmoset were trialed. On average, over 30% reduction in inflammatory cells of FBR on post mortem histology was noted across intervention groups. Similar strategies to those used in rodent models, including tip modification and flexible and sinusoidal electrode configurations, all produced good effects in histology; however, a notable absence of trials examining the effect on BCI end-function was noted. Future studies should assess whether the reduction in FBR correlates to an improvement in the functional effect of the intended BCI.
- Open Access
‘A silent epidemic of grief’: a survey of bereavement care provision in the UK and Ireland during the COVID-19 pandemic
Objectives To investigate the experiences and views of practitioners in the UK and Ireland concerning changes in bereavement care during the COVID-19 pandemic. Design Online survey using a snowball sampling approach. Setting Practitioners working in hospitals, hospices, care homes and community settings across the UK and Ireland. Participants Health and social care professionals involved in bereavement support. Interventions Brief online survey distributed widely across health and social care organisations. Results 805 respondents working in hospice, community, and hospital settings across the UK and Ireland completed the survey between 3 August and 4 September 2020. Changes to bereavement care practice were reported in: the use of telephone, video and other forms of remote support (90%); supporting people bereaved from non-COVID conditions (76%), from COVID-19 (65%) and people bereaved before the pandemic (61%); funeral arrangements (61%); identifying bereaved people who might need support (56%); managing complex forms of grief (48%) and access to specialist services (41%). Free-text responses demonstrated the complexities and scale of the impact on health and social care services, practitioners and their relationships with bereaved families, and on bereaved people. Conclusions The pandemic has created major challenges for the support of bereaved people: increased needs for bereavement care, transition to remote forms of support and the stresses experienced by practitioners, among others. The extent to which services are able to adapt, meet the escalating level of need and help to prevent a ‘tsunami of grief’ remains to be seen. The pandemic has highlighted the need for bereavement care to be considered an integral part of health and social care provision.
Open Access‘A silent epidemic of grief’: a survey of bereavement care provision in the UK and Ireland during the COVID-19 pandemic
Objectives To investigate the experiences and views of practitioners in the UK and Ireland concerning changes in bereavement care during the COVID-19 pandemic. Design Online survey using a snowball sampling approach. Setting Practitioners working in hospitals, hospices, care homes and community settings across the UK and Ireland. Participants Health and social care professionals involved in bereavement support. Interventions Brief online survey distributed widely across health and social care organisations. Results 805 respondents working in hospice, community, and hospital settings across the UK and Ireland completed the survey between 3 August and 4 September 2020. Changes to bereavement care practice were reported in: the use of telephone, video and other forms of remote support (90%); supporting people bereaved from non-COVID conditions (76%), from COVID-19 (65%) and people bereaved before the pandemic (61%); funeral arrangements (61%); identifying bereaved people who might need support (56%); managing complex forms of grief (48%) and access to specialist services (41%). Free-text responses demonstrated the complexities and scale of the impact on health and social care services, practitioners and their relationships with bereaved families, and on bereaved people. Conclusions The pandemic has created major challenges for the support of bereaved people: increased needs for bereavement care, transition to remote forms of support and the stresses experienced by practitioners, among others. The extent to which services are able to adapt, meet the escalating level of need and help to prevent a ‘tsunami of grief’ remains to be seen. The pandemic has highlighted the need for bereavement care to be considered an integral part of health and social care provision.
- Open Access
- 15 October 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (44) , 27646-27654
Cell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance
Significance: Recently, the field of Parkinson’s disease biology has shifted attention away from pure proteinotoxic hypotheses to emphasize primary cellular insults, including glycolipid disturbances. In this work, dopaminergic neurons in the Parkinson’s disease-vulnerable region of substantia nigra were found to accumulate neutral lipids, whereas in the same tissues, astrocytes have reduced lipid content, and resident microglia (a form of brain macrophage) show overall accumulation of lipids associated with inflammation. These changes were reproduced experimentally by blocking a specific lysosomal hydrolase in mice, generating a glycolipid accumulation in the animals. Based on these findings, it is reasonable to propose that restoring lipid homeostasis between neurons, astrocytes, and microglia could potentially influence PD pathogenesis and disease progression.
- 15 October 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (44) , 27646-27654
Open AccessCell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance
Significance: Recently, the field of Parkinson’s disease biology has shifted attention away from pure proteinotoxic hypotheses to emphasize primary cellular insults, including glycolipid disturbances. In this work, dopaminergic neurons in the Parkinson’s disease-vulnerable region of substantia nigra were found to accumulate neutral lipids, whereas in the same tissues, astrocytes have reduced lipid content, and resident microglia (a form of brain macrophage) show overall accumulation of lipids associated with inflammation. These changes were reproduced experimentally by blocking a specific lysosomal hydrolase in mice, generating a glycolipid accumulation in the animals. Based on these findings, it is reasonable to propose that restoring lipid homeostasis between neurons, astrocytes, and microglia could potentially influence PD pathogenesis and disease progression.